Nipro Markets Human iPS Cell Products To Pharmaceutical Companies In Japan
This article was originally published in PharmAsia News
Executive SummaryJapanese drug and device maker Nipro June 1 launched cardiomyocytes made from induced pluripotent stem cells to research institutions and pharmaceutical companies for cardiac research and new drug development. The first commercial products made from human iPS cells in Japan, the cardiomyocytes are manufactured by Tokyo-based biotech venture company ReproCell. Nipro signed a licensing agreement and obtained exclusive rights in Japan. Priced at ¥300,000 each kit consists of five cell clusters, Nipro estimates ¥20-¥50 million in annual sales. The cardiotoxicity assay allows the direct measurement of parameters in an invitro functional assay that comes close to invivo conditions. (Click here for more - Japanese language
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.